| Literature DB >> 28049284 |
Joon Ho Moon1,2, Soo Heon Kwak1,2, Hak C Jang1,3.
Abstract
Gestational diabetes mellitus (GDM), defined as any degree of glucose intolerance with onset or first recognition during pregnancy, is characterized by underlying maternal defects in the β-cell response to insulin during pregnancy. Women with a previous history of GDM have a greater than 7-fold higher risk of developing postpartum diabetes compared with women without GDM. Various risk factors for postpartum diabetes have been identified, including maternal age, glucose levels in pregnancy, family history of diabetes, pre-pregnancy and postpartum body mass index, dietary patterns, physical activity, and breastfeeding. Genetic studies revealed that GDM shares common genetic variants with type 2 diabetes. A number of lifestyle interventional trials that aimed to ameliorate modifiable risk factors, including diet, exercise, and breastfeeding, succeeded in reducing the incidence of postpartum diabetes, weight retention, and other obesity-related morbidities. The present review summarizes the findings of previous studies on the incidence and risk factors of postpartum diabetes and discusses recent lifestyle interventional trials that attempted to prevent postpartum diabetes.Entities:
Keywords: Clinical trial; Diabetes mellitus, type 2; Diabetes, gestational; Epidemiology; Risk factors
Mesh:
Year: 2017 PMID: 28049284 PMCID: PMC5214732 DOI: 10.3904/kjim.2016.203
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Figure 1.Cumulative incidence of type 2 diabetes after gestational diabetes mellitus pregnancy. CI, confidence interval. Adapted from Kwak et al. [36], with permission from Endocrine Society.
Figure 2.Genetic risk factors for early (≤ 8 weeks) and late (> 1 year) conversion to postpartum diabetes. ap value < with the signif icance after Bonferroni correction (0.05/10/2 = 0.0025).
Summary of representative studies for modifiable risk factors of postpartum diabetes
| Study | Ethnicity | Study subjects | Mean age (baseline), yr | Independent variable | Follow-up duration | Major findings | |
|---|---|---|---|---|---|---|---|
| Obesity | Peters et al. [ | Hispanic | 666 Women with previous GDM | 30 | Postpartum weight change | Mean 22 mon | Postpartum weight gain (10 lb) increased risk of postpartum diabetes by 1.95-fold |
| Bao et al. [ | Mostly Caucasians | 1,695 Women with a history of GDM from Nurses’ Health Study II | ~40 | Baseline BMI, most recent BMI, postpartum weight gain | 1991 to 2009 (median 14.0 yr) | Each 1 kg/m2 (~2.6 kg) increase in baseline BMI and most recent BMI increased postpartum diabetes by 16% and 16%. | |
| Each 5 kg increment of postpartum weight gain increased postpartum diabetes by 27%. | |||||||
| Moon et al. [ | Korean | 418 Women with previous GDM or gestational impaired glucose tolerance | 32 | Postpartum BMI change | Median 4.0 yr | Each 1 kg/m2 (~2.6 kg) increase in postpartum BMI change increases postpartum diabetes by 27%. | |
| Subjects in highest tertile (1.8 kg/m2) had 2 times higher risk of postpartum diabetes and worsened blood pressure and lipid profile compared to subjects in lowest tertile (–1.6 kg/m2) | |||||||
| Diet | Tobias et al. [ | Mostly Caucasians | 4,413 Women with a history of GDM from Nurses’ Health Study II | 38 | aMED, DASH, aHEI | 1991 to 2005 | Adherence to healthy diet (highest quartile of aMED, DASH, aHEI) had 40%, 46%, and 57% decreased risk of postpartum diabetes |
| Physical activity | Bao et al. [ | Mostly Caucasians | 4,554 Women with a history of GDM from Nurses’ Health Study II | 38 | Physical activity (MET-hour/week) | 1991 to 2007 | Higher physical activity (5 MET-hour/week or 100 minutes/week of moderate-intensity physical activity) decreased postpartum diabetes by 9%. |
| Increase in physical activity during follow-up (7.5 MET-hour/week or 150 minutes/week of moderate-intensity physical activity) decreased postpartum diabetes by 47%. | |||||||
| Breastfeeding | Ziegler et al. [ | German | 304 Women with previous GDM | 31 | Breastfeeding (and duration) | Up to 19 yr | Median time to postpartum diabetes was 12.3 years for women who breastfed vs. 2.3 years for women who did not breastfeed. |
| Women who breastfed for > 3 months had lower risk of diabetes than women who breastfed for ≤ 3 months ( |
GDM, gestational diabetes mellitus; BMI, body mass index; aMED, alternate Mediterranean diet; DASH, Dietary Approaches to Stop Hypertension; aHEI, alternate Healthy Eating Index; MET, metabolic equivalent of task.
Figure 3.Changes in insulin sensitivity (Matsuda index) and insulin secretory function (insulinogenic index) according to postpartum body mass index (BMI) change during 4 years of follow-up. Changes in insulin sensitivity and secretory function by tertiles of postpartum BMI change were depicted (open circle, initial postpartum visit; closed circle, last follow-up). Subjects in the first tertile (who lost weight during follow-up) showed improvements in both insulin sensitivity and insulin secretion, whereas subjects in the third tertile (who gained weight during follow-up) had significant deterioration in insulin sensitivity but were not able to compensate by increasing their insulin secretion during follow-up. Adapted from Moon et al. [45], with permission from Endocrine Society.
Summary of interventional trials for prevention of postpartum diabetes
| Study | Study design | Study subjects | Mean age (baseline) | Intervention | Follow-up duration | Major findings |
|---|---|---|---|---|---|---|
| TRIPOD [ | Intervention | High risk Hispanic women with previous GDM in the previous 4 years (266 women were randomized 1:1 to either troglitazone or placebo) | 34 yr | Troglitazone 400 mg/day | Median 30 mon | Annual diabetes incidence rate during postpartum was 12.1 and 5.4%/year in women assigned to placebo and troglitazone, respectively. |
| Troglitazone group showed reduction in endogenous insulin secretion (measured by IVGTT at 3 month). | ||||||
| PIPOD [ | Intervention | 95 women who were not diabetic at the end of TRIPOD study | 39 yr | Pioglitazone 30 mg/day, then increased to 45 mg/day | Median 35.9 mon | Annual diabetes incidence rate during postpartum was 4.6%/year, which was much lower than 12.1%/year in placebo group in TRIPOD study. |
| Pioglitazone stopped the decline in β-cell function that occurred during placebo treatment in the TRIPOD study. | ||||||
| DPPOS [ | 350 women with previous GDM and 1416 women with previous live births (DPP initially enrolled high risk subjects with impaired glucose tolerance) | 43 and 51 yr for women with and without previous history of GDM, respectively | ILS vs. metformin (850 mg twice a day) vs. placebo | 10 yr | ILS reduced incidence of diabetes compared with placebo by 40% (11.4 and 7.6/100 person-years in placebo and ILS, respectively). | |
| DEBI [ | Intervention | 197 women with GDM (enrolled during pregnancy) | Not available | Diet, exercise and breastfeeding Intervention | 1 yr | Higher proportion of women reached postpartum weight goal who underwent intervention (37.5 vs. 21.4%, |
| The intervention decreased dietary fat intake and increased breastfeeding. | ||||||
| Chinese study [ | Intervention | 450 Chinese women with either impaired glucose tolerance or diabetes by 75 g OGTT during pregnancy | 39 yr | Dietary advice and exercise | 3 yr | Fewer women developed diabetes who underwent lifestyle intervention (15% vs. 19%, |
| BMI, systolic and diastolic blood pressure, and triglyceride concentration were lower with intervention. |
TRIPOD, The Troglitazone in Prevention of Diabetes; GDM, gestational diabetes mellitus; IVGTT, intravenous glucose tolerance test; PIPOD, The Pioglitazone in Prevention of Diabetes; DPPOS, Diabetes Prevention Program Outcomes Study; DPP, Diabetes Prevention Program; ILS, intensive lifestyle intervention; DEBI, Diet, Exercise, and Breastfeeding Intervention; OGTT, oral glucose tolerance test; BMI, body mass index.